Price T Rowe Associates Inc Genprex, Inc. Transaction History

Price T Rowe Associates Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.76 - $1.78 $9,880 - $23,140	-13,000 Reduced 50.78%	12,600 $12,000
Q4 2022 Feb 14, 2023	SELL	$1.0 - $58.8 $41,900 - $2.46 Million	-41,900 Reduced 62.07%	25,600 $37,000
Q3 2022 Nov 14, 2022	SELL	$1.32 - $58.0 $17,028 - $748,200	-12,900 Reduced 16.04%	67,500 $96,000
Q2 2022 Aug 15, 2022	BUY	$1.28 - $2.31 $4,224 - $7,623	3,300 Added 4.28%	80,400 $112,000
Q4 2021 Feb 14, 2022	BUY	$1.21 - $2.7 $36,663 - $81,810	30,300 Added 64.74%	77,100 $101,000
Q3 2021 Nov 15, 2021	BUY	$2.59 - $3.36 $23,569 - $30,576	9,100 Added 24.14%	46,800 $125,000
Q2 2021 Aug 16, 2021	BUY	$3.11 - $4.87 $1,698 - $2,659	546 Added 1.47%	37,700 $126,000
Q1 2021 May 17, 2021	SELL	$3.66 - $7.67 $13,176 - $27,612	-3,600 Reduced 8.83%	37,154 $160,000
Q4 2020 Feb 16, 2021	BUY	$3.03 - $5.51 $123,484 - $224,554	40,754 New	40,754 $169,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $39.9M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.